Madrigal Pharmaceuticals (NASDAQ:MDGL) had its target price boosted by equities researchers at Evercore ISI from $65.00 to $140.00 in a research note issued to investors on Thursday, The Fly reports. The firm presently has an “outperform” rating on the biopharmaceutical company’s stock. Evercore ISI’s target price would suggest a potential upside of 60.59% from the stock’s current price.

Other research analysts also recently issued reports about the company. HC Wainwright boosted their price objective on Madrigal Pharmaceuticals from $54.00 to $105.00 and gave the company a “buy” rating in a research note on Wednesday. JMP Securities upped their price target on Madrigal Pharmaceuticals from $63.00 to $125.00 and gave the stock an “outperform” rating in a research note on Wednesday. Finally, Roth Capital set a $82.00 price target on Madrigal Pharmaceuticals and gave the stock a “buy” rating in a research note on Thursday, November 30th. One equities research analyst has rated the stock with a hold rating and four have issued a buy rating to the company’s stock. The company has an average rating of “Buy” and an average target price of $113.00.

Shares of Madrigal Pharmaceuticals (MDGL) traded up $40.88 during trading hours on Thursday, hitting $87.18. The stock had a trading volume of 3,218,600 shares, compared to its average volume of 57,582. Madrigal Pharmaceuticals has a 12 month low of $13.09 and a 12 month high of $101.00.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last announced its quarterly earnings data on Thursday, November 9th. The biopharmaceutical company reported ($0.68) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.79) by $0.11. sell-side analysts predict that Madrigal Pharmaceuticals will post -2.57 earnings per share for the current fiscal year.

Hedge funds have recently bought and sold shares of the stock. SG Americas Securities LLC acquired a new position in Madrigal Pharmaceuticals during the 3rd quarter worth approximately $100,000. New York State Common Retirement Fund acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter worth approximately $109,000. JPMorgan Chase & Co. acquired a new position in Madrigal Pharmaceuticals during the 3rd quarter worth approximately $325,000. California State Teachers Retirement System acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter worth approximately $117,000. Finally, TIAA CREF Investment Management LLC acquired a new position in Madrigal Pharmaceuticals during the 2nd quarter worth approximately $120,000. 21.40% of the stock is currently owned by institutional investors and hedge funds.

TRADEMARK VIOLATION WARNING: This piece of content was first posted by American Banking News and is owned by of American Banking News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.americanbankingnews.com/2017/12/07/madrigal-pharmaceuticals-mdgl-price-target-raised-to-140-00.html.

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc, formerly Synta Pharmaceuticals Corp., is a clinical-stage biopharmaceutical company. The Company focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular-metabolic diseases and nonalcoholic steatohepatitis (NASH). The Company’s lead product, MGL-3196, is a Phase II-ready once-daily, oral, liver-directed selective thyroid hormone receptor-b (THR-b) agonist for the treatment of NASH, and heterozygous and homozygous familial hypercholesterolemia (FH).

The Fly

Receive News & Ratings for Madrigal Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Madrigal Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.